Ionis insider plans sale of 4,141 common shares

Ionis Pharmaceuticals has a planned insider sale of common stock reported under Rule 144.

Rhea-AI Filing Summary

Ionis Pharmaceuticals has a planned insider sale of common stock reported under Rule 144. The filing covers the potential sale of 4,141 shares of Ionis common stock through broker Morgan Stanley Smith Barney, with an aggregate market value of $315,484.80. The notice lists total common shares outstanding as 161,137,930 and identifies NASDAQ as the exchange where the shares are to be sold. The securities were acquired as RSUs granted under the 2011 Equity Incentive Plan and treated as compensation.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Ionis (IONS) shares are planned to be sold under this Rule 144 notice?

The planned sale covers 4,141 shares of Ionis Pharmaceuticals common stock, as disclosed in the Rule 144 securities information table.

What is the aggregate market value of the Ionis (IONS) shares to be sold?

The filing reports an aggregate market value of $315,484.80 for the 4,141 Ionis common shares covered by this planned sale.

Which broker is handling the planned sale of Ionis (IONS) shares?

The common stock covered by this notice is to be sold through Morgan Stanley Smith Barney, located at 1585 Broadway, New York, NY 10036.

On which exchange are the Ionis (IONS) shares in this Rule 144 filing to be sold?

The notice identifies NASDAQ as the securities exchange where the Ionis Pharmaceuticals common shares are to be sold.

How were the Ionis (IONS) shares in this Rule 144 filing acquired?

The 4,141 shares were acquired as RSUs granted under the 2011 Equity Incentive Plan from Ionis Pharmaceuticals and are characterized as compensation.

How many Ionis (IONS) common shares are outstanding according to this filing?

The Rule 144 notice lists 161,137,930 Ionis Pharmaceuticals common shares as outstanding in the securities information section.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/16/2026 - 06:43 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002102721
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	IONIS PHARMACEUTICALS INC
SEC File Number	000-19125
Address of Issuer	2855 GAZELLE COURT CARLSBAD CALIFORNIA 92010
Phone	7609319200
Name of Person for Whose Account the Securities are To Be Sold	Kordasiewicz Holly B.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney 1585 Broadway New York NY 10036	4141	315484.80	161137930	01/16/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/15/2026	RSUs granted under 2011 Equity Incentive Plan	Ionis Pharmaceuticals			4141	01/15/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	01/16/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Holly Kordasiewicz
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)